Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.48 |
| ▸ | PPARG | P37231 | 7/20 | 0.48 |
| ▸ | PPARD | Q03181 | 7/20 | 0.48 |
| ▸ | PPARA | Q07869 | 7/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | FABP4 | P15090 | 2/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2183805 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL16342359 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL2037115 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL16323109 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL557403 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL25176741 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL414546 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL2182221 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL20897215 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL28595399 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113759048-B | Inspection method of mono-tert-butyl octadecanedioate | 成都普康唯新生物科技有限公司 | 2022-06-21 | — | — | CN | claimed |
| CN-113759048-A | Inspection method of mono-tert-butyl octadecanedioate | 成都普赛唯新生物科技有限公司 | 2021-12-07 | — | — | CN | claimed |
| US-20260132182-A1 | CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS | NOVO NORDISK AS (DK) | 2026-05-14 | — | — | US | disclosed |
| US-12583900-B2 | Peptide conjugates and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2026-03-24 | — | — | US | disclosed |
| US-12577259-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260071223-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260001928-A1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | CORTERIA PHARMACEUTICALS (FR) | 2026-01-01 | — | — | US | disclosed |
| EP-4482578-B1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | CORTERIA PHARMACEUTICALS (FR) | 2025-12-24 | — | — | EP | disclosed |
| EP-4646213-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE | Arrowhead Pharmaceuticals, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250332264-A1 | GhR-BINDING PEPTIDE AND COMPOSITION COMPRISING SAME | PEPTIDREAM INC (JP) | 2025-10-30 | — | — | US | disclosed |
| US-20250325683-A1 | LONG-ACTING DUAL GIP/GLP-1 PEPTIDE CONJUGATES AND METHODS OF USE | SCRIPPS RESEARCH INST (US) | 2025-10-23 | — | — | US | disclosed |
| US-20070129284-A1 | Single-chain insulin | NOVO NORDISK A/S (DK) | 2007-06-07 | — | — | US | disclosed |
| WO-2007009894-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2007-01-25 | — | — | WO | disclosed |
| EP-1692168-A1 | SINGLE-CHAIN INSULIN | NOVO NORDISK A/S (DK) | 2006-08-23 | — | — | EP | disclosed |
| US-20060183668-A1 | Antidiabetic agents; insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the alpha-amino group of the N-terminal amino acid residue of the B chain or to epsilon-amino group of a Lys residue present in the B chain of parent insulin | NOVO NORDISK A/S (DK) | 2006-08-17 | — | — | US | disclosed |
| WO-2006082205-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006082204-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2006-08-10 | — | — | WO | disclosed |
| EP-1660531-A2 | NOVEL INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005054291-A1 | SINGLE-CHAIN INSULIN | NOVO NORDISK A/S (DK) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005012347-A2 | NOVEL INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132182-A1 | CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS | GLP1R, GCGR, GIPR | TSHR 250/4885LMNA 3349/4885NFKB1 2929/4885 |
| US-12583900-B2 | Peptide conjugates and methods of use | GIPR, GLP1R, GCG | TSHR 15/4885LMNA 3974/4885NFKB1 4818/4885 |
| US-20250325683-A1 | LONG-ACTING DUAL GIP/GLP-1 PEPTIDE CONJUGATES AND METHODS OF USE | GLP1R, GIPR, GCGR | TSHR 142/4885LMNA 4176/4885NFKB1 4546/4885 |
| US-20260071223-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE | FABP4, PLIN1, PLIN3 | TSHR 1154/4885LMNA 977/4885NFKB1 4616/4885 |
| US-20250332264-A1 | GhR-BINDING PEPTIDE AND COMPOSITION COMPRISING SAME | GHRHR, GHSR, GIPR | TSHR 23/4885LMNA 4434/4885NFKB1 1480/4885 |
| US-12577259-B2 | PCSK9 antagonist compounds | PCSK9, LDLR, PCSK6 | TSHR 187/4885LMNA 395/4885NFKB1 1439/4885 |
| US-20070129284-A1 | Single-chain insulin | IGF1R, IGFBP1, INSR | TSHR 154/4885LMNA 759/4885NFKB1 2128/4885 |
| US-20260001928-A1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | GIPR, NPY2R, NPY1R | TSHR 388/4885LMNA 2248/4885NFKB1 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.